TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00229008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ceftobiprole plus placebo
Description: ceftobiprole 500 mg every 8 hours as a 120 minute intravenous infusion and placebo administered every 12 hours as a 60-minute intravenous infusion for 7 to 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: linezolid plus ceftazidime
Description: linezolid 600 mg every 12 hours as a 60-minute intravenous infusion plus ceftazidime 2 g every 8 hours as a 120-minute intravenous infusion for 7 to 14 days
Study: NCT04091399

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stamatological tamponade Contipro
Description: The drug is composed from the Hyaluronic acid and Octenidine dihydrochloride. It is designed to perform comparatively in pain alleviation and to promote healing of the alveolar osteitis while avoiding the side effects.
Study: NCT02929810

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: sleep extension

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: sleep maintenance
Study: NCT02065466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Study: NCT02061631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Pharmaceutical form:solution Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOCETAXEL XRP6976
Description: Pharmaceutical form:solution Route of administration: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Pharmaceutical form:tablet Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Pharmaceutical form:solution Route of administration: intravenous
Study: NCT03436979

Intervention type: DEVICE
Intervention: NeuGuide™ System
Description: The NeuGuide™ device is indicated for anchoring sutures to ligaments of the pelvic floor.
Study: NCT00265239

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: edaravone
Description: intravenous administration of 30mg Edaravone just before reperfusion therapy
Study: NCT04734431

Intervention type: BIOLOGICAL
Intervention: Eosinophil count
Description: Evaluation of the eosinophil count from admission to day 7

Intervention type: BIOLOGICAL
Intervention: Eosinophil count
Description: Evaluation of the eosinophil count from admission to day 7
Study: NCT04059276

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: We will examine chronic (\>3 months post stroke) patients using functional, structural, and metabolic MRI in both the brain and the spinal cord.

Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: We will examine healthy control participants using functional, structural, and metabolic MRI in both the brain and the spinal cord.
Study: NCT01068431

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: bandaging with trico as active controller
Description: In general non-elastic bandaging is the compression treatment in lymphedema

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: bandaging with trico as active controller
Description: In general non-elastic bandaging is the compression treatment in lymphedema
Study: NCT02639884

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SedLine EEG
Study: NCT03911960

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: 2 in person and 5 telephone sessions of acceptance and commitment therapy for tobacco cessation plus up to 8 weeks of nicotine patch

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: 2 in person sessions of tobacco cessation counseling, up to 8 weeks of nicotine patch, referral to state quitline.
Study: NCT02639884

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RRa monitoring
Study: NCT02162810

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: In order to analyze the data, we will establish a chart which will show the degree of cosmetic appearance, incidences and degree of complications. This we be assessed on a mild to severe scale.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo-controlled
Description: In order to analyze the data, we will establish a chart which will show the degree of cosmetic appearance, incidences and degree of complications. This we be assessed on a mild to severe scale.
Study: NCT03295201

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active cycle of breathing techniques (ACBT)
Description: ACBT involves three phases (Breathing control, chest expansion exercise, and huff coughing). These phases will apply with a sequence to remove secretion. ACBT will apply 1 per a week for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Active cycle of breathing techniques (ACBT)
Description: ACBT involves three phases (Breathing control, chest expansion exercise, and huff coughing). These phases will apply with a sequence to remove secretion. ACBT will apply 1 per a week for 6 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postural Exercise
Description: Postural exercise program will include thoracic vertebra mobilization, pectoral stretching, scapula and thoracic extensors strengthening and core stability exercises. Postural exercise program will apply 1 per a week for 6 weeks.
Study: NCT04455919

Intervention type: OTHER
Group type: OTHER
Intervention: Wait-list group
Description: The wait-list group benefit from a 8-week yoga program after the interventional group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga group
Description: During 8 weeks, the intervention group attended weekly yoga sessions and had to practice poses at home
Study: NCT00389324

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immune Globulin Intravenous (Human)
Description: This trial was an open-label, single-sequence, study. The enrolled subjects received IGIV-C via two routes of administration (IV for 4 -5 weeks and SC for 24 weeks) in order to compare the PK variables, safety and tolerability of SC administration of IGIV-C. Certain subjects required IV IGIV-C dosing during a Run-in Phase (3 - 4 months) for steady-state conditions prior to the IV phase. Subjects received two IV infusions of IGIV (between 200 - 600 mg based on the subject's previous IgG dosing regimen, 3 to 4 weeks apart) until a steady-state was reached at which time PK profiling was performed. Subjects began weekly SC administration (1.37 times the weekly equivalency of each subject's monthly IV dose) 1 week following last IV dose and followed for a period of six months.
Study: NCT01200121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Patients will receive paracentesis as needed for symptom con¬trol. In addition, patients will receive up to 4 intraperitoneal administrations of 400 mg Bevacizumabafter paracentesis has been performed. During the 8-week treatment period, a minimum interval of 14 days will be kept between applications of the study medication.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients will receive paracentesis as needed for symptom con¬trol. In addition, patients will receive up to 4 intraperitoneal administrations of Placebo after paracentesis has been performed. During the 8-week treatment period, a minimum interval of 14 days will be kept between applications of the study medication.
Study: NCT04908891

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical Scapular protocol (ClinScaP)
Description: the psychometric properties of two tests: Clinical Scapular protocol (ClinScaP) in PwMS and healthy controls.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical Scapular protocol (ClinScaP)
Description: the psychometric properties of two tests: Clinical Scapular protocol (ClinScaP) in PwMS and healthy controls.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: the prevalence of trunk, scapula and upper limb impairments.
Description: To investigate the prevalence of trunk, scapula and upper limb impairments in PwMS and stroke patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the prevalence of trunk, scapula and upper limb impairments.
Description: To investigate the prevalence of trunk, scapula and upper limb impairments in PwMS and stroke patients.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: the interaction between trunk, scapula and upper limb impairments.
Description: To investigate the interaction between trunk, scapula and upper limb impairments in PwMS and stroke patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: the interaction between trunk, scapula and upper limb impairments.
Description: To investigate the interaction between trunk, scapula and upper limb impairments in PwMS and stroke patients.
Study: NCT04726709

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Poised for Parkinson's
Description: Lecture, demonstration, activities, and supplemental materials designed to improve self-awareness, situational awareness, and ability to make good choices for physical and emotional self-care, moment-to-moment.
Study: NCT03089424

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PBMT
Description: The PBMT treatments will be performed using the Multi Radiance Medical™ Super Pulsed Laser MR4™ console (Solon, OH, USA), with the LS50 (emitter with an area of 20 cm2) and SE25 (emitter with an area of 4 cm2) cluster probes as emitters. Nine sites will be irradiated at patient's lumbar region: 3 central sites, using the SE25 (without any dose, 0 J); and 6 sites in the same direction, but laterally (both sides, 3 at a side), using the LS50 (without any dose, 0 J). Patients will be treated during 12 sessions over a period of four weeks (three sessions/week). At each treatment session, patients will receive a total dose of 0 J. At the end of the 12 treatment sessions, patients will receive a total dose of 0 J.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PBMT active
Description: The PBMT treatments will be performed using the Multi Radiance Medical™ Super Pulsed Laser MR4™ console (Solon, OH, USA), with the LS50 (emitter with an area of 20 cm2) and SE25 (emitter with an area of 4 cm2) cluster probes as emitters. Nine sites will be irradiated at patient's lumbar region: 3 central sites, using the SE25 (3000 Hz of frequency, 3 minutes of irradiation per site, 24.75 J per site, a totalizing 74.25 J irradiated from SE25); and 6 sites in the same direction, but laterally (both sides, 3 at a side), using the LS50 (1000 Hz of frequency, 3 minutes of irradiation per site, 24.30 J per site, a total of 145.80 J irradiated from LS50). Patients will be treated during 12 sessions over a period of four weeks (three sessions/week). At each treatment session, patients will receive a total dose of 220.05 J. At the end of the 12 treatment sessions, patients will receive a total dose of 2640.60 J.
Study: NCT03599063

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06946860
Description: PF-06946860 administered subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06946860
Description: PF-06946860 administered subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06946860
Description: PF-06946860 administered subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06946860
Description: PF-06946860 administered subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06946860
Description: PF-06946860 administered subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06946860
Description: PF-06946860 administered subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06946860
Description: PF-06946860 administered subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PF-06946860
Description: PF-06946860 administered subcutaneously

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, administered subcutaneously

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, administered subcutaneously

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, administered subcutaneously

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, administered subcutaneously
Study: NCT03976076

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JBPOS0101
Description: JBPOS0101 (investigational product)
Study: NCT03087773

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 10 mg
Description: The subject will receive Empagliflozin 10 mg orally once daily for 26 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: The subject will receive Placebo orally once daily for 26 weeks.
Study: NCT00138645

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Diet
Description: Participants randomized to the Healthy Diet group will be prescribed a traditional food-based diet that contains the same number of kilocalories (1200/day) as the MicroDiet but will be instructed not to use meal replacements
Study: NCT01601821

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CsA+Rapamune+CS
Description: Part 1: Rapamune will be given as a loading dose of 6 mg once followed by maintenance dose of 2 mg to achieve a target trough level of 8-15 ng/ml. Part 2: Rapamune dose will be adjusted to achieve a target trough level of 10-15ng/ml through 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CsA+MMF+CS
Description: The control arm is the standard local practice (official protocol) in Iran:~Cyclosporine + MMF + Corticosteroid. The time period is from pre-study screening / baseline evaluation up to 12 months for patients who are maintained on CsA + MMF + CS.
Study: NCT03067506

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT02740660

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine 100mg / Albuterol 4mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family weight management counseling
Study: NCT00598156

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib (Tarceva)
Description: Chemotherapy for 18 weeks (XELOX, XELIRI, FOLFOX or FOLFIRI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab (Avastin)
Description: Chemotherapy for 18 weeks (XELOX, XELIRI, FOLFOX or FOLFIRI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab (Avastin)
Description: Chemotherapy for 18 weeks (XELOX, XELIRI, FOLFOX or FOLFIRI)
Study: NCT02368977

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Third Eye Panoramic device
Description: A Third Eye Panoramic device will be attached to the tip of the colonoscope and will provide two additional views from laterally-oriented video cameras during the colonoscopy procedure.
Study: NCT04362111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anakinra
Description: The active treatment group will receive anakinra 100 mg subcutaneously every 6-12 hours for a period of 10 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: The control group will receive normal saline placebo subcutaneously every 6-12 hours for period of 10 days
Study: NCT03296488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nalbuphine Sebacate
Description: intramuscular single dose of NALDEBAIN 24±12 hours before surgery.
Study: NCT03599063

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, administered subcutaneously

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, administered subcutaneously

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, administered subcutaneously

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo, administered subcutaneously
Study: NCT00235534

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate initiation of OCPs

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Delayed initiation of OCPs
Study: NCT02233660

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy Group
Description: The physical therapy group will receive 3 treatment sessions of manual therapies including maneuvers targeted to the areas anatomically related to the median nerve (i.e., cervical spine, shoulder, elbow and wrist) of 30min of duration, once per week.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical Group
Description: The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
Study: NCT03111225

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: massage
Description: a 15 minutes thoracic massage will be added to the regular physical therapy treatment
Study: NCT04351152

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lenzilumab
Description: Administered as an intravenous (IV) infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Standard of care therapy can include remdesivir and/or dexamethasone per institutional treatment guidelines or written policies

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Standard of care therapy can include remdesivir and/or dexamethasone per institutional treatment guidelines or written policies
Study: NCT01465334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofatumumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-Dose Methylprednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High-Dose Methylprednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Study: NCT02740660

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Family weight management counseling
Study: NCT01304563

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TIV 2010/2011 influenza vaccine
Description: TIV 2010/2011 influenza vaccine Intramuscular: 15 mcg TIV 2010/2011 vaccine x 1: Control

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TIV 2010/2011 influenza vaccine
Description: Low dose TIV 2010/2011 influenza vaccine delivered via intradermal injection x 1: Experimental

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TIV 2010/2011 influenza vaccine
Description: Higher lower dose TIV 2010/2011 influenza vaccine delivered via intradermal injection x 1: Experimental

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: INT
Description: Low dose TIV 2010/2011 influenza vaccine delivered via a short needle intradermal device x 1: Experimental
Study: NCT00447694

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: Oral deferasirox 30mg/kg/day once per day for 77 weeks.
Study: NCT01453101

Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine monophosphate, melphalan, Bortezomib
Description: * Fludarabine will be administered at a dose of 30/mg/m2 IV daily for 4 days starting on transplant day -5.~* Melphalan will be administered at a dose of 140 mg/m2 on transplant day-2~* Bortezomib will be administered by rapid IV push at a dose of 1.6mg/m2 on days-4 and -1. The bortezomib should be given at least 20 hours after the melphalan.
Study: NCT02377687

Intervention type: OTHER
Intervention: observational study
Study: NCT00549107

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milrinone
Study: NCT01835808

Intervention type: DEVICE
Intervention: Fractional flow reserve (St. Jude Medical pressure-wire)
Description: CAD patients submitted to coronary angiography and in which coronary lesions are to be evaluated with pressure-wire (FFR functional evaluation)
Study: NCT04876807

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-196
Description: In Parts 1, 2, and 3, participants will receive oral Dose 1 of ACP-196 (reference or acidic formulation as applicable) on Day 1, Day 3, Day 8, and Day 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-196
Description: In Parts 1, 2, and 3, participants will receive oral Dose 1 of ACP-196 (reference or acidic formulation as applicable) on Day 1, Day 3, Day 8, and Day 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACP-196
Description: In Parts 1, 2, and 3, participants will receive oral Dose 1 of ACP-196 (reference or acidic formulation as applicable) on Day 1, Day 3, Day 8, and Day 10.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Participants will receive omeprazole in all parts as: on Day 8 and Day 10 with water in Part 1; on Day 8 with water and on Day 10 with acidic beverage in Part 2; on Day 8 with water and on Day 10 with grapefruit juice in Part 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Participants will receive omeprazole in all parts as: on Day 8 and Day 10 with water in Part 1; on Day 8 with water and on Day 10 with acidic beverage in Part 2; on Day 8 with water and on Day 10 with grapefruit juice in Part 3.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Participants will receive omeprazole in all parts as: on Day 8 and Day 10 with water in Part 1; on Day 8 with water and on Day 10 with acidic beverage in Part 2; on Day 8 with water and on Day 10 with grapefruit juice in Part 3.
Study: NCT04443673

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Glycine
Description: Along with habitual treatment for their severe condition, participants will receive 0.5 g/kg/day glycine by nasogastric tube, divided in four equal doses in a day, since their enrollment and until they are weaned from mechanical ventilator or die.
Study: NCT00571220

Intervention type: PROCEDURE
Intervention: gastric bypass surgery
Description: weight loss bariatric surgery

Intervention type: OTHER
Intervention: Diet induced weight loss
Description: low calorie diet with meal replacements. weekly outpatient visits with nutritionist.
Study: NCT01781689

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Functional Electric Stimulation
Description: apply to the hemiplegia affected limbs, helping movement

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Rehabilitation programs
Description: include occupational therapy and physical therapy